Real-time enrollment status for this relapsed or refractory acute myeloid leukemia (aml) clinical trial
Current Status
Recruiting
Checked: August 28, 2026 at 5:06 PM UTC
| NCT Number | NCT02074839 |
| Recruiting Status | Recruiting |
| Condition | Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| Phase | PHASE1 |
| Target Enrollment | 291 participants |
| Active Locations | 26 sites in the US |
| Sponsor | Institut de Recherches Internationales Servier |
| Last Updated on CT.gov | June 15, 2026 (Jun 15, 2026) |
As of August 28, 2026: Clinical trial NCT02074839 is currently recruiting participants. This phase1 study for relapsed or refractory acute myeloid leukemia (aml) is actively seeking new participants at 26 locations across the United States. The study is sponsored by Institut de Recherches Internationales Servier. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT02074839 is actively recruiting participants as of August 28, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 26 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT02074839 was last updated Jun 15, 2026 (June 15, 2026). HelloStudys verifies this status automatically.